Lupin Stock

Lupin Goodwill

The Goodwill of Lupin (LUPIN.NS) as of Aug 18, 2026 is 22.33 B INR. In the previous year, Goodwill was 23.25 B INR — a change of -3.98% (lower).

Goodwill

22.33 BINR

YoY

-3.98%

Last updated:

Goodwill of Lupin is 2026 22.33 B INR. Goodwill of Lupin was 2025 23.25 B INR. It decreases by -3.98% lower compared to the previous year.
Access this data via the Eulerpool API

Lupin Stock analysis

What does Lupin do? Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners. Lupin is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lupin stock

Goodwill of Lupin is 22.33 B INR in 2026.

Goodwill of Lupin changed from 23.25 B INR to 22.33 B INR, representing a -3.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Lupin since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Lupin historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Lupin

All Key Metrics — Lupin